Stryker Co. (NYSE:SYK) Shares Purchased by Mogy Joel R Investment Counsel Inc.

Mogy Joel R Investment Counsel Inc. boosted its stake in Stryker Co. (NYSE:SYK - Free Report) by 3.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 98,216 shares of the medical technology company's stock after acquiring an additional 3,218 shares during the period. Stryker accounts for about 2.4% of Mogy Joel R Investment Counsel Inc.'s holdings, making the stock its 15th biggest position. Mogy Joel R Investment Counsel Inc.'s holdings in Stryker were worth $36,561,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Elefante Mark B acquired a new position in Stryker during the 4th quarter worth approximately $337,000. Ferguson Wellman Capital Management Inc. boosted its stake in shares of Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after acquiring an additional 3,341 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of Stryker during the 1st quarter worth approximately $1,840,000. Metis Global Partners LLC boosted its stake in shares of Stryker by 10.2% during the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after acquiring an additional 1,561 shares in the last quarter. Finally, Fred Alger Management LLC boosted its stake in shares of Stryker by 415.8% during the 4th quarter. Fred Alger Management LLC now owns 24,011 shares of the medical technology company's stock worth $8,664,000 after acquiring an additional 19,356 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 0.9%

NYSE SYK traded down $3.48 during trading hours on Friday, hitting $377.01. 876,021 shares of the company's stock were exchanged, compared to its average volume of 1,332,895. The business's 50 day moving average is $372.73 and its 200-day moving average is $375.66. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm has a market capitalization of $143.90 billion, a P/E ratio of 48.58, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same period in the prior year, the business posted $2.50 earnings per share. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. As a group, analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. Stryker's dividend payout ratio (DPR) is 45.41%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

SYK has been the topic of several research analyst reports. Truist Financial boosted their price target on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research note on Monday, May 5th. BTIG Research set a $403.00 price target on Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Evercore ISI decreased their price target on Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Roth Mkm boosted their price target on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.